De Pardieu has advised the Banks of the French laboratory Biosynex, specializing in rapid tests, biotherapy monitoring and molecular biology, on the negotiation and conclusion of an agreement on the terms of its financial debt restructuring.
The agreement pertains to the restructuring of Biosynex’s financial debt of nearly €65 million and, in particular, the credit facilities previously granted by its banking partners.
At the same time, and in order to enhance its financial structure, Biosynex has launched in January 2025 a capital increase with preferential subscription right for a target amount of nearly €8 million, to enable each shareholder to participate in this transaction to strengthen the net equity. Settlement-delivery of this capital increase is expected on 14 February 2025.